AzurRx   Report issue

For profit Phase 2
Founded: Brooklyn NY United States (2011)
Status: Acquired by First Wave Bio, Inc. (2021)

Organization Overview

First Clinical Trial
2017
NCT03481803
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

AzurRx BioPharma, Inc. | AzurRx SAS

Active Ingredients

Drugs in Phase 2 Trials (3)

ms1819-sd (4 trials)

niclosamide (nicloside) (1 trial)

pancreatin (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cystic Fibrosis (Phase 2)

Digestive System Diseases (Phase 2)

Exocrine Pancreatic Insufficiency (Phase 2)

Fibrosis (Phase 2)

Gastrointestinal Diseases (Phase 2)

Pancreatitis (Phase 2)

Pancreatitis, Chronic (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 3